Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$6.05
-$0.19(-8.12%)
At close: 4:00 PM EST
$6.05
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$2.59 - $1,823.04
Previous CloseN/A
Volume180.10K
Average Volume (3M)42.67K
Market Cap
$2.24M
Enterprise Value-$1.30M
Total Cash (Recent Filing)$18.79M
Total Debt (Recent Filing)$13.92M
Price to Earnings (P/E)―
Beta3.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding809,584
10 Day Avg. Volume15,777
30 Day Avg. Volume42,671
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-0.50
Enterprise Value/Gross Profit-4.89
Enterprise Value/Ebitda0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp increase in trailing revenue indicates that PMGC is expanding its commercial activity and gaining greater market reach. Although profitability remains unproven, sustained sales growth can improve operating leverage and provide a larger base for future commercialization if margins recover.
Recurring Royalty ReceivablesConverting the Elevai royalty into scheduled payments creates a more predictable, non-dilutive source of cash through 2031. This improves visibility around future receipts and gives PMGC a durable financial asset that can support operations or acquisitions without immediate equity issuance.
AI Cardiometabolic PipelineThe program gives PMGC exposure to potentially large cardiometabolic markets through four candidates and an exclusive field of use. Planned validation, lead selection, and IND-enabling preparation could build longer-term pipeline value if the compounds reproduce their early laboratory results.
Bears Say
Severe UnprofitabilityThe combination of sharply lower gross margin and substantial operating and net losses shows that revenue growth has not translated into an economically sustainable model. Persistent losses reduce reinvestment capacity and leave future growth dependent on a meaningful improvement in commercial economics.
Ongoing Cash BurnContinued operating and free cash outflows mean PMGC is consuming substantial cash rather than funding expansion internally. This weakens financial resilience and increases the likelihood that ongoing operations, development programs, or acquisitions will require external capital.
Rising LeverageThe rapid increase in debt relative to equity raises financial risk while returns remain deeply negative. Greater leverage can constrain capital allocation, add repayment obligations, and reduce flexibility if losses continue or the company needs additional funding for its pipeline.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $2.58 and its highest was $1823.04 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $2.24M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 809,584 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―
Ownership Overview
41.21%
Insiders
― Other Institutional Investors
58.58% Public Companies and
Individual Investors